Market Closed -
Other stock markets
|
|
Pre-market 07:13:13 am | ||
29.28 USD | +1.28% | 29.44 | +0.56% |
07:48am | Valneva: recruitment completed for VALOR trial | CF |
06:29am | Pfizer, Valneva Conclude Enrollment in Late-stage Study of Lyme Disease Vaccine | MT |
Evolution of the average Target Price on Pfizer, Inc.
Price target over the last 5 years
History : Analyst Recommendations
5763679f3e40fb.bZW5OUEr4V_RF2aghc1sO_s2OjmL_AU4CTv8Ko-IqSY.Ptnbbyp8pifnfiDWzKA-coxRUnG8vk9CYGqEXvvq2V8F8vVeLH3UMo5eKw~e40a430f02eadfedbd92552e67ebb4fa
More recommendations
Analysts' Consensus
Sell
Buy

Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
29.28USD
Average target price
40.41USD
Spread / Average Target
+38.02%
High Price Target
75USD
Spread / Highest target
+156.15%
Low Price Target
32USD
Spread / Lowest Target
+9.29%
Consensus detail
Consensus revision (last 18 months)
Analysts covering Pfizer, Inc.
JPMORGAN | Chris Schott |
UBS | Trung Huynh |
Barclays | |
Morgan Stanley | |
JEFFERIES | Akash Tewari |
Jefferies & Co. | |
Wells Fargo Securities | |
JPMorgan Chase | |
BMO Capital | |
SVB Securities LLC | |
Credit Suisse | |
Goldman Sachs | |
Truist Securities | |
HSBC | |
Berenberg Bank | |
BERENBERG | Kerry Holford |
Daiwa Securities | |
BofA Securities | |
Atlantic Equities | |
Citigroup | |
Mizuho Securities | |
Atlantic Securities | |
SVB Leerink | |
Independent Research | |
Cantor Fitzgerald | |
RBC | |
RBC Capital Markets | |
J.P. Morgan Chase | |
DZ Bank |
Trading Rating :
Investor Rating :
ESG Refinitiv :
C+
EPS Revisions
- Stock
- Equities
- Stock Pfizer, Inc. - Nyse
- Consensus Pfizer, Inc.